Document Detail


Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management.
MedLine Citation:
PMID:  18097728     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Intraductal papillary mucinous neoplasms (IPMNs) show varying degrees of dysplasia throughout the neoplasm that can range from adenoma to invasive carcinoma, with dysplastic changes of borderline neoplasms and carcinoma in situ in between. An understanding of the natural history, and especially the required time to transform into either carcinoma in situ or an invasive adenocarcinoma, is critically important for management policy. This topic serves as the rationale for the present analysis. At the beginning of February 2007, using the key word "IPMN" in PubMed, we initially selected 119 publications using the principal criteria as defined by the WHO classification. We identified 20 appropriate original reports and one consensus paper. Neither randomized control trials (RCT) or systematic reviews of RCTs (level 1 evidence) nor cohort studies or reviews of cohort studies (level 2 evidence) have been published. Only one report fit the criteria for level 3 evidence (case control study). Nineteen papers satisfied criteria for level 4 (cases series) and two for level 5 (expert opinion publication). After additional review and analysis, we considered only six reports to be "cornerstone papers" of merit for the final review. Clues to the natural history of IPMNs can be gained by using several methods to examine the articles: (a) to verify different prognoses between main and side branch duct subtypes; (b) to compare the average age of patients with benign vs. malignant IPMNs; (c) to summarize the findings of nonoperative, observational studies based on follow up by clinical, biochemical, and imaging techniques without operative resection; (d) to determine the prognostic importance of the status of the resection margin; and (e) to follow patients clinically after surgical resection. Although important aspects of the natural history of IPMN are still unknown, the following conclusions can be drawn: (1) Branch-duct IPMNs are less aggressive than main-duct IPMNs. (2) Malignancy is more common in older patients. (3) Malignancy (invasive or carcinoma in situ) is found in about 70% of resected main-duct IPMNs. (4) After resection of noninvasive IPMNs (branch- and main-duct varieties), recurrence is rare (<8%). (5) After resection of invasive IPMN, recurrence occurs in 50-65% of patients.
Authors:
Claudio Bassi; Michael G Sarr; Keith D Lillemoe; Howard A Reber
Related Documents :
21146858 - Interobserver variability in histologic evaluation of radical prostatectomy between cen...
21277098 - Phase ii study of concomitant thalidomide during radiotherapy for hepatocellular carcin...
9372378 - Gallbladder carcinoma: a 28 year experience.
24106948 - Treatment of acute promyelocytic leukemia.
24304648 - Circulating microrna expressions in colorectal cancer as predictors of response to chem...
348228 - A controlled trial of puncture sites for amniocentesis.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-12-19
Journal Detail:
Title:  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract     Volume:  12     ISSN:  1091-255X     ISO Abbreviation:  J. Gastrointest. Surg.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-14     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9706084     Medline TA:  J Gastrointest Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  645-50     Citation Subset:  IM    
Affiliation:
Department of Surgery and Gastroenterology, G.B. Rossi BorgoRoma Hospital, University of Verona, 37134 Verona, Italy. Claudio.bassi@univr.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma, Mucinous* / therapy
Adenocarcinoma, Papillary* / therapy
Carcinoma, Pancreatic Ductal* / therapy
Humans
Pancreatic Neoplasms* / therapy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patients do not know the level of training of their doctors because doctors do not tell them.
Next Document:  TGF-beta1 and high levels of glucose do not increase insulin cell proportions in the avian embryonic...